Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 8/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452270 | 0.93 | PTPN11 (0.46) | PTPN11DHODHTP53THRATHRB | |
| SCHEMBL15459687 | 0.91 | PTPN11 (0.41) | PTPN11TP53THRATHRBPTPN1 | |
| SCHEMBL15247976 | 0.86 | L3MBTL1 (0.52) | PTPN11DHODHCNR2 | |
| SCHEMBL4572111 | 0.83 | CYP1A2 (0.47) | THRATHRBCNR2 | |
| SCHEMBL10137170 | 0.82 | BCHE (0.37) | PTPN11THRATHRBCNR2PTPN1 | |
| SCHEMBL17733191 | 0.81 | DHODH (0.45) | PTPN11DHODH | |
| SCHEMBL15459724 | 0.81 | L3MBTL1 (0.48) | PTPN11DHODH | |
| SCHEMBL15452269 | 0.81 | L3MBTL1 (0.48) | PTPN11DHODHTHRATHRBCNR2 | |
| SCHEMBL10070479 | 0.79 | PTPN11 (0.40) | PTPN11DHODHTP53WDR5CNR2 | |
| SCHEMBL13556899 | 0.79 | PTPN11 (0.40) | PTPN11DHODHTP53WDR5CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463280-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | PTPN11 522/4885DHODH 1783/4885TP53 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.